"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
CRISPR Therapeutics has a 12-month low of $38.20 and a 12-month high of $91.10. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of -14.59 and a beta of 1.68.
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio ... including life sciences research tools, kits and reagents; discovery of novel targets for ...
At-home test kits offer a convenient way to monitor health conditions privately, using advanced technologies for accurate and ...
In practice, automation makes it possible to edit, isolate, and screen thousands of clones for desired genetic changes made with CRISPR-Cas9 and transposase-based systems, ensuring that the best ...
The nonprofit will offer survivors comprehensive home kits including furniture, kitchenware, bedding, cleaning supplies and health and hygiene products. By Kirsten Chuba Events Editor Nonprofit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback